Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
12.82
-1.34 (-9.46%)
At close: Apr 10, 2025, 4:00 PM
12.80
-0.02 (-0.17%)
After-hours: Apr 10, 2025, 8:00 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 24, with a low estimate of 18 and a high estimate of 30. The average target predicts an increase of 87.21% from the current stock price of 12.82.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2025.
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +56.01% | Mar 6, 2025 |
| UBS | UBS | Strong Buy Maintains $30 → $27 | Strong Buy | Maintains | $30 → $27 | +110.61% | Jan 30, 2025 |
| Barclays | Barclays | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +102.81% | Jan 30, 2025 |
| UBS | UBS | Strong Buy Maintains $28 → $30 | Strong Buy | Maintains | $28 → $30 | +134.01% | Jan 23, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $23 → $30 | Buy | Maintains | $23 → $30 | +134.01% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
17.42B
from 16.54B
Increased by 5.31%
Revenue Next Year
17.63B
from 17.42B
Increased by 1.18%
EPS This Year
2.59
from -1.45
EPS Next Year
2.69
from 2.59
Increased by 3.99%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 18.2B | 19.0B | 19.8B |
| Avg | 17.4B | 17.6B | 18.1B |
| Low | 16.5B | 16.5B | 16.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.0% | 8.8% | 12.4% |
| Avg | 5.3% | 1.2% | 2.7% |
| Low | -0.3% | -5.6% | -5.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.70 | 2.92 | 3.11 |
| Avg | 2.59 | 2.69 | 2.92 |
| Low | 2.46 | 2.42 | 2.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 12.8% | 15.6% |
| Avg | - | 4.0% | 8.4% |
| Low | - | -6.5% | -0.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.